Ovid Therapeutics (OVID) Share-based Compensation (2016 - 2026)

Ovid Therapeutics has reported Share-based Compensation for 11 years, with the latest figure at $1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 18.54% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.6 million (down 18.29% YoY), and the FY2025 full-year result was $4.8 million, down 23.41% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.0 million, down from $1.2 million in the prior quarter.
• The five-year high for Share-based Compensation was $2.0 million in Q1 2024, with the low at $1.0 million in Q1 2026.
• Historically, Share-based Compensation has averaged $1.5 million across 5 years, with a median of $1.6 million in 2023.
• Annual changes were most pronounced in 2022 — Share-based Compensation jumped 53.37% — and 2025, when it sank 34.76%.
• Ovid Therapeutics' Share-based Compensation stood at $1.7 million in 2022, then gained by 3.43% to $1.8 million in 2023, then fell by 29.57% to $1.3 million in 2024, then slipped by 5.16% to $1.2 million in 2025, then declined by 12.47% to $1.0 million in 2026.
• The last three Share-based Compensation figures came in at $1.0 million (Q1 2026), $1.2 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.